These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 35529089)

  • 1. The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts.
    Ferrario CM; Groban L; Wang H; Sun X; VonCannon JL; Wright KN; Ahmad S
    Kidney Int Suppl (2011); 2022 Apr; 12(1):36-47. PubMed ID: 35529089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical potential of renin inhibitors and angiotensin antagonists.
    Cody RJ
    Drugs; 1994 Apr; 47(4):586-98. PubMed ID: 7516858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
    Li XC; Zhang J; Zhuo JL
    Pharmacol Res; 2017 Nov; 125(Pt A):21-38. PubMed ID: 28619367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future of angiotensin II inhibition in cardiovascular medicine.
    Meier P; Maillard M; Burnier M
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Feb; 5(1):15-30. PubMed ID: 15720221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current strategies to achieve further cardiac and renal protection through enhanced renin-angiotensin-aldosterone system inhibition.
    Alfie J; Aparicio LS; Waisman GD
    Rev Recent Clin Trials; 2011 May; 6(2):134-46. PubMed ID: 21241234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update of the blockade of the renin angiotensin aldosterone system in clinical practice.
    Márquez DF; Ruiz-Hurtado G; Ruilope LM; Segura J
    Expert Opin Pharmacother; 2015; 16(15):2283-92. PubMed ID: 26389772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
    Jacobsen P; Rossing K; Parving HH
    Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition.
    Atlas SA
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl B):9-20. PubMed ID: 17970613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The renin-angiotensin-aldosterone system: a specific target for hypertension management.
    Weir MR; Dzau VJ
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):205S-213S. PubMed ID: 10619573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the renin angiotensin aldosterone system: focus on aliskiren.
    Rao MS
    J Assoc Physicians India; 2010 Feb; 58():102-8. PubMed ID: 20653151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertension: renin-angiotensin-aldosterone system alterations.
    Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
    Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease.
    Reyes S; Varagic J; Ahmad S; VonCannon J; Kon ND; Wang H; Groban L; Cheng CP; Dell'Italia LJ; Ferrario CM
    Curr Hypertens Rep; 2017 Feb; 19(2):16. PubMed ID: 28233239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of renin-angiotensin-aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension.
    Xu W; Yang YM; Zhu J; Wu S; Wang J; Zhang H; Shao XH
    BMC Cardiovasc Disord; 2022 Apr; 22(1):141. PubMed ID: 35365067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease.
    Brewster UC; Perazella MA
    Am J Med; 2004 Feb; 116(4):263-72. PubMed ID: 14969655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
    Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
    Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.
    Ferrario CM; Mullick AE
    Pharmacol Res; 2017 Nov; 125(Pt A):57-71. PubMed ID: 28571891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
    Martin N; Manoharan K; Davies C; Lumbers RT
    Cochrane Database Syst Rev; 2021 May; 5(5):CD012721. PubMed ID: 34022072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.